GlaxoSmithKline Capital Inc, founded in 2000 and headquartered in London, UK, serves as the financing arm of the global healthcare company GlaxoSmithKline plc. The company focuses on providing capital to support its parent’s extensive pharmaceutical and consumer healthcare product lines.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| GSK 3.63% 2025-05-15 USDGlaxosmithkline Capital Inc | United Kingdom | 2025-05-15 | 3.625 | 0.00 |
| GSK 3.88% 2028-05-15 USDGlaxosmithkline Capital Inc | United Kingdom | 2028-05-15 | 3.875 | 3.87 |
| GSK 4.20% 2043-03-18 USDGlaxosmithkline Capital Inc | United Kingdom | 2043-03-18 | 4.200 | 5.22 |
| GSK 4.50% 2030-04-15 USDGlaxosmithkline Capital Inc | United Kingdom | 2030-04-15 | 4.500 | 4.13 |
| GSK 4.88% 2035-04-15 USDGlaxosmithkline Capital Inc | United Kingdom | 2035-04-15 | 4.875 | 4.75 |
| GSK 5.38% 2034-04-15 USDGlaxosmithkline Capital Inc | United Kingdom | 2034-04-15 | 5.375 | 4.53 |
| GSK 6.38% 2038-05-15 USDGlaxosmithkline Capital Inc | United Kingdom | 2038-05-15 | 6.375 | 5.02 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Since its inception, GlaxoSmithKline Capital Inc has established a robust bond issuance program, with its debut bond issuance occurring in 2001. Notable issuances include a landmark $3 billion green bond in 2020 aimed at funding sustainability initiatives, positioning the company favorably in the current market. As of 2023, current yields on their bonds are competitive within the industry, appealing to investors seeking stable returns, complemented by features such as callable options that enhance liquidity under favorable market conditions.